Unsuccessful Regulatory Filings for Biosimilar Approval: A Comprehensive Review

A recent paper in Expert Opinion on Biological Therapy studies failed fillings for biosimilar drugs. Over the past three decades, biotherapeutics have revolutionized healthcare by providing effective treatments for complex diseases that were previously challenging to manage with traditional small molecule pharmaceuticals. With the expiration or imminent expiry of patents on several biotherapeutics, the market for […] Source